Medivation & Pfizer to terminate their collaboration to market development of Dimebon

February 6th, 2012|

USA-based Medivation (NASDAQ: MDVN) and global drugs behemoth Pfizer (NYSE: PFE) have finally decided to discontinue the development of Dimebon also known as latrepirdine, for all indications and will terminate the ongoing open label extension study in Alzheimer’s disease.

Canadian Pharma Market Research Conference 2012

February 6th, 2012|

Leading Pharma industry experts plan to be at the Pharma Market Research Conference which takes place on February 7-8 at the Hilton Parsippany Hotel in New Jersey.

Antares Pharma Licenses A Drug Delivery Technology To Pfizer

January 10th, 2012|

Antares Pharma has recently announced that it has licensed to Pfizer Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. The companies did not disclose specifics of the deal.

Research partnership between Humana and Pfizer

January 4th, 2012|

Humana, one of the nation's largest health care companies, and Pfizer, the world's largest biopharmaceutical company, have recently linked together to explore new ideas and ways to improve the quality, outcomes and costs of the health care delivery system for senior citizens and other population.

FDA Warns Against Usage of Needle Free Flu Vaccine

January 3rd, 2012|

Recently, US Food and Drug Administration (FDA) has advised health providers not to use needle free injector devices to administer influenza vaccines, because so far no flu vaccines have been approved for administration using such devices, saying they are approved for only the measles, mumps and rubella vaccine.

Indian pharmaceutical industry has tremendous potential to grow from the current levels

February 19th, 2010|

A highly organized sector, the Indian pharmaceutical industry is estimated to be worth $4.5 billion, growing at about 8% to 9% every year.

GlaxoSmithKline Pharma: In sound health

February 18th, 2010|

Sales growth and control on costs helped improve margins.Improved sales across its four business units helped GlaxoSmithKline Pharmaceuticals record an 18 per cent year-on-year growth in gross sales to Rs 453 crore for the December 2009 quarter. This, coupled with lower excise outgo, helped the company post a better-than-expected 20 per cent year-on-year jump in net sales.

Pharmaceutical Advantage For India

February 18th, 2010|

The Indian drug industry could make huge gains as over $70 billion worth of drugs are expected to go off patent in the US, the world’s largest pharma market, in the next three years.

Reddy formula

February 18th, 2010|

If a shareholder had invested about Rs 2,500 in Dr Reddy's Laboratories through the IPO in August 1986 and the rights issue of 1989, what do you think the holding would be worth today? A whopping Rs 40 lakh!

Brit scientists find way to store vaccines in room temp

February 18th, 2010|

Scientists may have finally found a way to deal with one of developing world's worst problems in healthcare — faulty and inadequate cold chain for vaccine storage. British scientists from Oxford University have found a way to keep vaccines stable even in room temperature.

Russia invites Indian pharmas for joint ventures

February 16th, 2010|

Russia today invited Indian pharmaceutical companies to set up joint ventures in the country.

HarNeedi.com to organise job fair for healthcare and pharma in Mumbai

February 15th, 2010|

HarNeedi.com, India’s No. 1 job portal for Healthcare and Pharma industry, will be organizing an exclusive ‘Healthi Job Fair 2010’ for Healthcare and Pharma 'Healthi Job Fair 2010' at the Bombay Exhibition Center, Western Express Highway, Goregaon East, Mumbai on March 20 and 21, 2010.

Indian pharma in midst of corporate transformation

February 15th, 2010|

Surging growth and global operations ensure they can’t be family-run any longer.

From Oceans to Crops, and From Crops to IPO

February 14th, 2010|

Avesthagen’s systems biology approach to novel products targets more than land based organisms – dives deep into new products from the OceanAvesthagen has always been in the forefront of innovative scientific thinking and has developed a formidable portfolio of patents in all the four areas it operates in viz. bioAgriculture, bioNutrition, bioPharmacueticals and in Science & Innovation.  Approximately 600 patent applications cover both, process and products. There are several copyrights and design patents as well.  Within each area Avesthagen aspires to benefit the common man, and more so for the “bottom of the pyramid”.

Expectation of Indian Pharmaceuticals and Health Science Industry

February 10th, 2010|

After witnessing a neutral budget last year, the Indian pharmaceutical industry has prepared itself again with its wish list for Budget 2010.

Cipla retains top slot in domestic pharma market

February 8th, 2010|

Drug company Cipla maintained its top position in the domestic market for the 12 months ended December, 2009, with a market share of 5.38 per cent — up 18 per cent over the year and ahead of Ranbaxy Laboratories and GlaxoSmithKline (GSK).

Technopark TBI Virtual Incubatee Catalyz Scientific Technologies bags ISBA Award for the Best Start

February 7th, 2010|

Catalyz is developing affordable diagnostic and care systems for infectious and chronic diseases. The tests need no technical knowledge or any device to interpret the result, hence making it easy for a lame man in confirming or ruling out certain diseases.

Innovation is the key to pharma sector futureĀ 

February 7th, 2010|

The collapse of the property market has left the economy with a huge hole that will be difficult to fill. One of the few sectors that offers hope of growth is the pharmaceutical industry, with senior executives convinced that genuine opportunities remain for Ireland Inc.

Troikaa Pharma to get US patent for its Dyanapar AQ

February 7th, 2010|

Troikaa Pharmaceuticals, a Gujarat based fast growing healthcare company, is likely to get US patent for its novel drug delivery form of Diclofenac injections-Dyanapar AQ.

No place like home, finds Indian pharma

February 7th, 2010|

In a recent reversal, operations abroad are hampering profit.